pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,054 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT793Endpoints596BioPharma Dive230onclive165BioSpace67Fierce Biotech67raps29
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • Opinion: RFK Jr.’s antidepressant deprescribing push gets one thing right — and others dangerously wrong
    “Deprescribing requires gradual tapering, psychological support, careful risk stratification, and accessible alternatives — none of which Kennedy’s initiative provides at scale.”
    STAT · 2mo ago↗ source
  • <![CDATA[Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast Cancer]]>
    <![CDATA[Kelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond]]>
    <![CDATA[Dr Nunnery and Annie Bond discuss breast cancer survivorship and patient advocacy.]]>
← prev
page 31 of 43
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
onclive · 2mo ago
↗ source
  • <![CDATA[AUA and SUO Amend Advanced Prostate Cancer Guideline]]>
    <![CDATA[The AUA and SUO released the 2026 amendment to the Advanced Prostate Cancer Guideline.]]>
    onclive · 2mo ago↗ source
  • STAT+: Why Marty Makary was the worst FDA commissioner in 25 years
    Marty Makary, who resigned under pressure from the FDA, brought to the job a fundamental lack of understanding of the nature of the role, STAT's Matthew Herper writes.
    STAT · 2mo ago↗ source
  • <![CDATA[Dr Postow on an Ideal Post-ICI Monitoring Framework in Melanoma ]]>
    <![CDATA[Michael A. Postow, MD, discusses the importance of long-term multidisciplinary follow-up for patients with melanoma treated with ICIs.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Postow on the Timing of Delayed or Re-Emergent irAEs in Melanoma]]>
    <![CDATA[Michael A. Postow, MD, discusses the evolving understanding of ICIs in melanoma and the unique toxicity profiles associated with these agents.]]>
    onclive · 2mo ago↗ source
  • Males who discuss suicide seek help less often than females, report finds
    Out of 1.5 million messages received in 2025, the Crisis Text Line found that less then 20% of the texters identified as male only
    STAT · 2mo ago↗ source
  • STAT+: European Union inks a draft deal to boost local production of medicines and avoid shortages
    The E.U. reached a provisional deal to strengthen the supply of essential medicines and avoid shortages by ‌boosting domestic production and reducing reliance on imports.
    STAT · 2mo ago↗ source
  • STAT+: Makary departs FDA amid turmoil as Diamantas, agency’s top food official, steps in
    Food and Drug Administration Commissioner Marty Makary is resigning from his role after a tumultuous tenure.
    STAT · 2mo ago↗ source
  • Supreme Court extends mifepristone deadline
    The deadliest drug in the country, the new name for PCOS, and more health news from Morning Rounds
    STAT · 2mo ago↗ source
  • STAT+: Hims takes a $33 million hit from GLP-1 ‘pivot’
    In this edition of STAT Health Tech: Hims earnings, Omada's PBM strategy, and the uphill battle faced by new sepsis algorithms.
    STAT · 2mo ago↗ source
  • STAT+: Hims’ sales miss as telehealth competition grows
    Bristol's partnership with Hengrui Pharma, Viiv loses HIV treatment case, and more biotech news from The Readout
    STAT · 2mo ago↗ source
  • <![CDATA[Temple Health’s Fox Chase Cancer Center and Labcorp Collaborate to Test Ultra-Sensitive Blood-Based Assay for Early-Stage Lung Cancer Recurrence Risk]]>
    <![CDATA[A Fox Chase Cancer Center study will evaluate a tumor-informed, whole-genome sequencing–based test to assess recurrence risk in early-stage NSCLC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Grants Breakthrough Therapy Designation to Emi-Le for Adenoid Cystic Carcinoma]]>
    <![CDATA[Emi-Le received breakthrough therapy designation from the FDA for the treatment of patients with locally advanced, recurrent or metastatic ACC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[[177Lu]Lu-D-Dan-Phe-PSMA Demonstrates Manageable Safety and Early Efficacy mCRPC ]]>
    <![CDATA[[177Lu]Lu-D-Dan-Phe-PSMA showed early signals of safety and activity in mCRPC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Issues Warning Regarding Risk of Secondary Primary Malignancies With Tazemetostat in Follicular Lymphoma, Epithelioid Sarcoma ]]>
    <![CDATA[The FDA issued a warning about the risk of secondary primary malignancies associated with tazemetostat in epithelioid sarcoma and follicular lymphoma. ]]>
    onclive · 2mo ago↗ source
  • STAT+: STAT examines America’s deadliest drug
    STAT examines America's failure to address excessive alcohol use across decades.
    STAT · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and more
    The 17 pharmaceutical companies anchoring TrumpRx poured more than $130 million into federal lobbying in 2025 — a nearly 23% surge
    STAT · 2mo ago↗ source
  • <![CDATA[GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026]]>
    <![CDATA[We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Unmet Needs in Endometrial Cancer]]>
    <![CDATA[Important unmet needs remain in endometrial cancer even as antibody drug conjugates begin to expand the therapeutic armamentarium.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[EGFR-Mutated NSCLC: Mechanism and Clinical Role of TROP2-Directed ADCs]]>
    <![CDATA[In this segment, Dr. Sands asks the panel to discuss the emerging role of TROP2-directed antibody–drug conjugates in EGFR-mutated non-small cell lung cancer. Dr. Wakelee and Dr. Cooper exp…
    onclive · 2mo ago↗ source
  • <![CDATA[Future Directions in Relapsed and Refractory Multiple Myeloma ]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Parikh on the Feasibility and Importance of Immunotherapy Trials in Anal Cancer ]]>
    <![CDATA[Aparna R. Parikh, MD, discusses how trials like PODIUM-303 are reshaping the treatment paradigm for squamous cell anal carcinomas. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Sequencing Strategies After Progression in Multiple Myeloma ]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source